FDA-authorized CaRi-Heart software analyzes inflammation in the fat surrounding coronary arteries and combines it with clinical information to estimate cardiovascular mortality risk, pointing toward a future where routine CT scans reveal biological danger invisible to conventional measurements of artery narrowing.
Anthropic’s new Model Hardware Standard allows artificial-intelligence agents to control microscopes, liquid handlers, robotic arms and other physical laboratory equipment, creating a path toward autonomous drug-discovery laboratories capable of designing, running and adjusting experiments around the clock.
BEACONPredict and a growing body of research are testing whether artificial intelligence can use routine CT imaging to predict malignant cerebral edema before neurological deterioration, potentially shifting stroke care from emergency reaction toward preventive intervention.
A new Philips and Imricor interventional MRI platform brings cardiac procedures inside a 1.5-tesla MRI environment, advancing a longer-term effort to replace indirect X-ray guidance with direct tissue visualization.
Generative artificial intelligence is pushing medical software beyond fixed predictions toward systems capable of conversation, synthesis and potentially autonomous actions. The FDA is now exploring whether these devices should be evaluated more like clinical professionals than conventional software.
FcRn normally rescues IgG antibodies from intracellular destruction and returns them to circulation. Blocking that recycling pathway accelerates IgG clearance, including pathogenic autoantibodies, without directly eliminating the B cells that produced them.
Radiofrequency burns and cryoballoon freezes cardiac tissue to isolate pulmonary veins. Pulsed field ablation instead uses microsecond electrical pulses to disrupt myocardial cells, offering a nonthermal route that may reduce collateral injury while delivering comparable rhythm control.
Conventional CAR-T therapy turns one patient’s T cells into one personalized drug batch through collection, genetic engineering, expansion, testing and release. Faster autologous, allogeneic and in-vivo approaches are trying to collapse that process from weeks toward days.
Hyaluronidase temporarily clears a molecular barrier inside subcutaneous tissue, allowing large antibody doses to disperse and absorb from injection volumes that would otherwise be impractical.
The blood-brain barrier protects neurons by tightly controlling molecular traffic, but the same biology excludes many antibodies, enzymes and nucleic-acid medicines. Drug developers are increasingly hijacking the barrier’s own transport systems rather than trying simply to disrupt it.